Business
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nWorld’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan.\n\n\nResults consistent with durable complete responses recently reported in Triple Negative Breast Cancer (TNBC) when off-the-shelf CD-16 NK therapy was combined with ImmunityBio’s N-803.\n\n\nOver 130 doses of PD-L1.t-haNK cells safely administered in Phase 1 trial with no severe treatment-related adverse side effects.\n\n\nNantKwest plans to initiate registration trials in recurrent metastatic TNBC and pancreatic cancer patients that failed standard of care.\n\n\nN-803 received Breakthrough Designation from the FDA for BCG Unresponsive CIS non-muscle invasive bladder cancer.\n\n\nNantKwest plans to apply for Breakthrough Therapy Designation for advanced TNBC and pancreatic cancer.\n\n\n\n \n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nNantKwest Inc., (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced results from their Phase 1 trial investigating a novel, first-in-human immunotherapy consisting of NantKwest’s off-the-shelf, PD-L1 tumor-targeted NK cells (NCT04050709). In addition, NantKwest and ImmunityBio, Inc., a privately held immunotherapy company, reported on a compassionate use expanded access IND combining the PD-L1-targeted NK cell with ImmunityBio’s IL-15 fusion protein (N-803) in a patient with metastatic pancreatic cancer who had relapsed after prior standard of care therapy.\n\n\nThe findings on the Phase 1 safety and early signals of efficacy were reported by Patrick Soon-Shiong, M.D., Chairman and CEO of NantKwest, at the J.P. Morgan Healthcare Conference in San Francisco.\n\n\n“We hypothesize that a common treatment protocol that harnesses both the natural-killer cell and the T cells could be effective in treating cancer across multiple tumor types. This has been supported by the early signals of safety and efficacy in Phase 1 and 2 studies of NantKwest’s natural killer cells in advanced cancers. We recently reported at the 2019 Society for Immunotherapy of Cancer conference (SITC) complete responses in third-line Merkel cell carcinoma and fourth-line head and neck cancers when ...